---

Market Overview

---

The global proteomics market witnessed a valuation of USD 25.13 billion in 2021, and it is projected to reach USD 50.69 billion by 2027, with a compound annual growth rate (CAGR) of 12.41%. This growth is driven by the increasing awareness among individuals about the applications of proteomics in drug discovery, biomarker identification, and clinical diagnostics for disease diagnosis and treatment. Numerous private and public research organizations are dedicated to developing proteomics based on spectrometry.

Proteomics, which involves the comprehensive study of proteins, is a rapidly growing field in disease diagnosis. It aims to identify disease-related proteins and analyze their structure, function, and expression. Due to the intricacies involved in proteomics, sophisticated technologies are crucial for providing actionable insights that advance the field. Proteomics plays a pivotal role in medical research as it allows for the large-scale investigation of proteins across various biological samples, leading to the discovery of new protein biomarkers for different diseases.

Proteomics enables the discovery of novel protein biomarkers for diagnostic applications and facilitates the exploration of molecular targets for medication development and discovery. It encompasses techniques such as protein expression profiling, targeted protein quantification, protein-protein interaction analysis, and post-translational modification analysis. Proteomics has proven its utility in biomarker identification, medication development, and precision medicine.

The impact of COVID-19 is also evident in the growth of the proteomics market. Extensive research has been conducted on diagnostics, biomarker discovery, and drug development against COVID-19, which has accelerated the adoption of proteomics. Many large and small companies have developed immunoassay kits for rapid COVID-19 detection. Additionally, numerous public and private research organizations and institutes have extensively utilized proteomics in their COVID-19 research.

Proteomics plays a significant role in drug development, leading many pharmaceutical manufacturers to establish proteomics divisions, thereby driving the global proteomics market’s growth.

Existing proteomics technologies face limitations such as lack of specificity in high-multiplex assays, limited sensitivity and precision, restricted dynamic range, high sample consumption, scalability issues, low throughput, data complexity, and high costs. However, these limitations are gradually being addressed, which will expand the scope of proteomics.

Proteomics technologies available in the market include spectrometry, microarray, chromatography, and reagents used for proteomic analysis. The analysis of proteome complexity at the amino acid variant level, which generates crucial biological insights, relies heavily on expensive and intricate techniques.

Nanoproteomics, offering real-time multiplexed analysis, rapid and miniaturized assays, low sample consumption, and high sensitivity, has emerged as a significant area for proteomic investigations. Its prominence presents considerable growth opportunities for market players. Although nanoproteomics is still in its early stages, continuous technological advancements are expected in the coming years. BGI, a China-based company, has extensive experience in nanoproteomics and offers nanoproteomics services in over 66 countries. Another company, Seer, provides an integrated solution called the photograph product suite, which incorporates proprietary engineered nanoparticles, consumables, automation instruments, and software to simplify proteomics studies. This commercial service has been adopted by providers in North America, Europe, and the Asia Pacific region.

The consumables and reagents segment holds the largest market share, accounting for 77.08% in 2021. Over several decades, both small and large companies have been tirelessly working to develop more reagents and consumables used in all areas of proteomics, particularly in sample preparation. Major companies like Agilent Technologies, Bio-Rad Laboratories, and Thermo Fisher Scientific offer a wide range of consumables and reagents. With the increasing research in proteomics worldwide, the reagent portfolio is expected to expand further. Consequently, the consumables and reagents segment generates the highest revenue, amounting to $19.37 billion in 2021.

---

Market Segmentation

---

The market is segmented based on various factors, including product, application, end-user, and geography.

Market Segmentation by Product
Consumables & Reagents
Instruments & Software
Services

Market Segmentation by Application
DDD & TR
Clinical
Applications
Forensic & Applied Proteomics

Market Segmentation by End-User
Pharma & Biotech
Academic & Research Institutes
Hospitals
Diagnostic & Forensic

Segmentation by Geography
North America – US, Canada
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan, India, South Korea, Australia
Latin America – Brazil, Mexico, Argentina
Middle East & Africa – South Africa, Saudi Arabia, Turkey

The instruments and software market is projected to grow at a compound annual growth rate (CAGR) of 13% from 2022 to 2027. Major companies in this market offer a wide range of instruments, including those for microarray, spectrometry, chromatography, electrophoresis, surface plasma resonance, and x-ray crystallography. The increasing focus on biomarker discovery and drug development has led to a greater implementation of instruments and software in laboratories of pharmaceutical companies and academic/research institutes. As a result, the instruments and software segment is expected to experience significant growth with a CAGR of 13% during the forecast period.

Among various end-users, the pharmaceutical and biotechnology companies segment is witnessing growth due to the demand for diagnostic tools in drug development. The surge in the use of proteomic technology is also attributed to the adoption of precision medicine, driven by the identification and discovery of biomarkers, particularly in response to the rising prevalence of chronic diseases such as cancer.

Several academic and research institutes are also major contributors to the proteomics market, conducting research on drug and vaccine development. Hospitals are utilizing proteomics technologies for disease diagnosis, either through their in-house pathology laboratories or by collaborating with diagnostic laboratories. Collaborations with proteomics companies enable these hospitals to access related proteomic technologies.

Forensic laboratories are also playing a significant role in driving the growth of the proteomics market. They receive substantial funding and investments to conduct research in forensic science, specifically for protein identification and biomarker discovery.

Pharmaceutical and biotechnology companies generate the highest revenue in the proteomics market, amounting to $11.76 billion in 2021. Academic and research institutes are the primary users of proteomics technologies for various research activities, including discovery, technological innovation, product advancements, and academic training. This segment is expected to grow at the highest CAGR of 12.91%.

Factors driving the global growth of the proteomics market include increasing adoption of personalized medicine, rising R&D expenditures for drug and biomarker discovery, and the development of precision medicine driven by biomarkers. Growing awareness among the public regarding the applications of proteomics in drug development, biomarker discovery, and clinical diagnostics is also contributing to market growth. Some private and public research organizations are focused on developing proteomics based on spectrometry.

In North America, Europe, and the APAC region, government funding for R&D activities provides growth opportunities for key players to develop advanced proteomics diagnostics and instruments during the forecast period. However, these regions face challenges due to a shortage of skilled professionals. The introduction of nanotechnology in proteomics is a growing trend in North America and the APAC region, offering significant opportunities for acceptance. For example, BGI Genomics in China provides nano proteomics services.

The Middle East, Africa, and Latin America are increasingly adopting precision medicine. Governments in these regions have initiated several initiatives to accelerate the growth of the proteomics market. The rising popularity of personalized medicine, increased research on biomarkers and drug discovery, are driving the proteomics market in Latin America, the Middle East, and Africa. However, stringent regulatory norms, high costs of proteomics instruments, lack of funds and investments, limited awareness about proteomics, and a shortage of skilled professionals are hindering the adoption of advanced proteomics approaches in these regions.

---

Competitive Landscape

---

Vendors in the proteomics market can be categorized as manufacturers and service providers. This market is highly dynamic and competitive, with a mix of global, regional, and local players offering a wide range of proteomics solutions. Agilent Technologies, Bio-Rad Laboratories, Thermo-Fisher Scientific, Danaher, and PerkinElmer are significant manufacturers providing proteomics products. On the other hand, BGI Group is a substantial service provider offering proteomics services.

Industry players are engaging in expansion activities, such as regional business expansions and facility expansions, to strengthen their global distribution networks and tap into untapped opportunities. They are also increasing their product launches, making significant investments in the single-use bioprocessing probes and sensors market through various conglomerates and investment firms. Additionally, collaborations and partnerships with established manufacturers, academic and research institutes, hospitals, and diagnostic and forensic laboratories are helping these players solidify their market presence. Strategic acquisitions remain a vital competitive strategy for key players to expand their product offerings, gain access to new technology, or increase market share.

In low and middle-income countries, there is a higher demand for service providers due to inadequate healthcare infrastructure. Service providers are actively focusing on increasing collaborations with hospitals and pharmaceutical companies to expand their presence in the market. The growing demand for proteomics research has attracted the attention of researchers from laboratories lacking advanced technologies or skilled professionals. As a result, many companies have emerged to provide services such as protein identification, quantification, sequencing, purification, and custom assay services.

Key companies profiled in this report include Agilent Technologies, Bio-Rad Laboratories, Danaher, Thermo Fisher Scientific, PerkinElmer, BGI Genomics, Bruker, DiaSorin, HORIBA, Illumina, INOVIQ, LI-COR, Nautilus Biotechnology, Proteome Factory, QIAGEN, Rhythm Biosciences, Shimadzu Scientific Instruments, Seer, Waters, Applied Biomics, Creative Proteomics, Poochon Scientific, SomaLogic, Vproteomics, Abcam, AnteoTech, AYOXXA Biosystems, Biognosys, Geneilabs, Grace Bio-Labs, ITSI-Biosciences, MSAID, Olink, Promega, Proteomics International, Quanterix.

---

Key Questions Answered

---

How large is the global proteomics market?

The global proteomics market was valued at USD 25.13 billion in 2021 and is projected to reach USD 50.69 billion by 2027.

What is the growth rate of the global proteomics market?

The global proteomics market is expected to grow at a compound annual growth rate (CAGR) of 12.41% during the period of 2022-2027.

Who are the key players in the global proteomics market?

The key players in the global proteomics market include Agilent Technologies, Bio-Rad Laboratories, Danaher, Thermo Fisher Scientific, PerkinElmer, and BGI Genomics.

What are the growth factors in the global proteomics market?

The growth factors in the global proteomics market include the increasing number of research and development activities in proteomics, rising prevalence of cancer and various genetic disorders, and growing focus on the development of precision medicine.

What are the latest trends in the global proteomics market?

The latest trends in the global proteomics market include advancements in mass spectrometry-based proteomics, the increasing prominence of nanoproteomics, and the use of proteomics in revolutionizing diabetes management.